Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | ARG1 | P05089 | 3/20 | 0.36 |
| ▸ | ARG2 | P78540 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL3094553 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL22157986 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL3100126 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL6276264 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1675387 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1675447 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL16038745 | 1.00 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL23834597 | 0.96 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL11660661 | 0.96 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1696608 | 0.96 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110582514-B | Conjugates of plasmin cleavable antibodies against insoluble fibrin with drugs | 国立研究开发法人国立癌症研究中心 | 2024-03-01 | — | — | CN | disclosed |
| US-20230132177-A1 | FIBRIN-BINDING ANTIBODY AND PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY | RIN INSTITUTE INC. (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4130269-A1 | FIBRIN-BINDING ANTIBODY AND PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY | National Cancer Center (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115461462-A | Antibody binding to fibrin and pharmaceutical composition comprising the same | 国立研究开发法人国立癌症研究中心 | 2022-12-09 | — | — | CN | disclosed |
| CN-114574536-A | Collagen tripeptide and enzymatic preparation method thereof | 华南理工大学 | 2022-06-03 | — | — | CN | disclosed |
| US-11311626-B2 | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate | NATIONAL CANCER CENTER JAPAN (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200147231-A1 | PLASMIN-CLEAVABLE ANTI-INSOLUBLE FIBRIN ANTIBODY-DRUG CONJUGATE | NATIONAL CANCER CENTER JAPAN (JP) | 2020-05-14 | — | — | US | disclosed |
| EP-3620471-A1 | PLASMIN-CLEAVABLE ANTI-INSOLUBLE FIBRIN ANTIBODY-DRUG CONJUGATE | National Cancer Center Japan (JP) | 2020-03-11 | — | — | EP | disclosed |
| CN-110582514-A | Conjugates of plasmin-cleavable anti-insoluble fibrin antibody and drug | 国立研究开发法人国立癌症研究中心 | 2019-12-17 | — | — | CN | disclosed |
| CN-107760747-A | A kind of industrialized production earthworm protein active peptide and preparation method | 林峰 | 2018-03-06 | — | — | CN | disclosed |
| CN-107760747-A | A kind of industrialized production earthworm protein active peptide and preparation method | 林峰 | 2018-03-06 | — | — | CN | disclosed |
| CN-1917869-A | Composition and method for use in cartilage affecting conditions | HILLS PET NUTRITION INC (US) | 2007-02-21 | — | — | CN | disclosed |
| CN-1756571-A | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNAT GMBH (CH) | 2006-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147231-A1 | PLASMIN-CLEAVABLE ANTI-INSOLUBLE FIBRIN ANTIBODY-DRUG CONJUGATE | PLAT, PLG, FGB | GSR 4497/4885DPP7 491/4885DPP4 620/4885 |
| US-11311626-B2 | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate | PLAT, PLG, FGB | GSR 4497/4885DPP7 491/4885DPP4 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.